Biotech startup Latus Bio has raised $42 million to fund a clinical trial for its gene therapy targeting Huntington's disease, with plans to seek FDA approval to begin the trial in the coming months. The company is also advancing a treatment for CLN2 disease, a severe genetic disorder.
Latus Bio's recent $42 million funding round to initiate a gene therapy clinical trial for Huntington’s disease presents a significant investment opportunity in the biotech sector, especially given their strategic pivot to address setbacks encountered by competitors in this space. As a professional tracking healthtech and biotech advancements, keeping an eye on Latus Bio's progress and their approach in overcoming past industry challenges could offer insights into successful clinical trial strategies and potential competitive advantages in gene therapy innovations.